Rehab Mohamed Ateya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rehab Mohamed Ateya has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Amira Afifi
Clinical Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
1 shared publication - Eman S Elgharabawy
Medical Microbiology and Immunology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
1 shared publication - Mahmoud M. Magdy
Internal Medicine Department, Al‐Sabah Hospital, Shuwaikh Industrial, Kuwait
1 shared publication - Mai M. Malek
Medical Microbiology and Immunology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
1 shared publication Mohamed Arafa
Department of Pediatrics, Faculty of Medicine, Zagazig University, Egypt
1 shared publication- Rania M. Amer
Zagazig University
1 shared publication
Latest Publications
- Open Access
- 31 December 2022
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 16 (12) , 1852-1859
Susceptibility of carbapenem-resistant Enterobacterales isolates to new antibiotics from a tertiary care hospital, Egypt: A matter of hope
Introduction: Carbapenem-resistant Enterobacterales (CRE) are particularly worrisome pathogens because of their resistance to last-resort antibiotics, significant morbidity, and mortality. With limited treatment options, new therapeutic choices have become available for the management of CRE infections. Data regarding the efficacy of these novel agents are still limited particularly in a low-middle-income country like Egypt. This study aims to assess the prevalence of different carbapenemase genes among CRE isolates and the susceptibility of these isolates to novel antibiotics for improving antibiotic policy and infection control strategies in Egypt. Methodology: In this cross-sectional study, 260 Enterobacterales were recovered from patients admitted to intensive care units between January and June 2021. Susceptibility testing was conducted using Kirby-Bauer method. Molecular detection of five carbapenemase genes, namely blaKPC, blaIMP, blaVIM, blaNDM, blaOXA-48 was done using polymerase chain reaction (PCR). Results: Of the 260 Enterobacterales, 34.6% were found to be carbapenems resistant. All of the CRE isolates were multi-drug resistant exhibiting resistance to most antibiotics. All isolates harbored one or more carbapenemases genes. The most prevalent was blaNDM (84.4%), followed by blaOXA-48 (73.3%), blaKPC (13.3%), blaIMP (2.2%), while blaVIM gene wasn’t detected. Among 62.2% of the CRE isolates, two or more carbapenemase genes co-existed. For the new antibiotics tested, 100% of CRE resisted ceftolozane/tazobactam, 86.7% resisted ceftazidime/avibactam, 51.1% were resistant to eravacyclin, and 42.2% were resistant to cefiderocol. Conclusions: A high percentage of resistance to carbapenems among Enterobacterales isolates was revealed. blaNDM was found to be the most predominant carbapenemase gene. A high rate of CRE resistance to novel agents signifies a major threat.
- 31 December 2022
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 16 (12) , 1852-1859
Open AccessSusceptibility of carbapenem-resistant Enterobacterales isolates to new antibiotics from a tertiary care hospital, Egypt: A matter of hope
Introduction: Carbapenem-resistant Enterobacterales (CRE) are particularly worrisome pathogens because of their resistance to last-resort antibiotics, significant morbidity, and mortality. With limited treatment options, new therapeutic choices have become available for the management of CRE infections. Data regarding the efficacy of these novel agents are still limited particularly in a low-middle-income country like Egypt. This study aims to assess the prevalence of different carbapenemase genes among CRE isolates and the susceptibility of these isolates to novel antibiotics for improving antibiotic policy and infection control strategies in Egypt. Methodology: In this cross-sectional study, 260 Enterobacterales were recovered from patients admitted to intensive care units between January and June 2021. Susceptibility testing was conducted using Kirby-Bauer method. Molecular detection of five carbapenemase genes, namely blaKPC, blaIMP, blaVIM, blaNDM, blaOXA-48 was done using polymerase chain reaction (PCR). Results: Of the 260 Enterobacterales, 34.6% were found to be carbapenems resistant. All of the CRE isolates were multi-drug resistant exhibiting resistance to most antibiotics. All isolates harbored one or more carbapenemases genes. The most prevalent was blaNDM (84.4%), followed by blaOXA-48 (73.3%), blaKPC (13.3%), blaIMP (2.2%), while blaVIM gene wasn’t detected. Among 62.2% of the CRE isolates, two or more carbapenemase genes co-existed. For the new antibiotics tested, 100% of CRE resisted ceftolozane/tazobactam, 86.7% resisted ceftazidime/avibactam, 51.1% were resistant to eravacyclin, and 42.2% were resistant to cefiderocol. Conclusions: A high percentage of resistance to carbapenems among Enterobacterales isolates was revealed. blaNDM was found to be the most predominant carbapenemase gene. A high rate of CRE resistance to novel agents signifies a major threat.
- Open Access
- 20 May 2021
- Published by Egyptian Knowledge Bank in Microbes and Infectious Diseases
Ceftazidime/ Avibactam Efficiency tested In Vitro against Carbapenem-resistant Klebsiella pneumoniae isolated from Neonates with Sepsis
Background: Carbapenem-resistant Klebsiella pneumoniae (CRKP) emergence and dissemination, is an important healthcare concern due to its limited therapeutic options. Ceftazidime/avibactam (CAZ/AVI) is a recently approved antibiotic combination that may be effective in treating these resistant infections. The current study aimed to determine the prevalence of CRKP among clinical isolates from the neonatal intensive care unit (NICU) and to evaluate the in-vitro activity of CAZ/AVI against them. Methods: A total of 255 clinical samples were collected from neonates with suspected sepsis. All Klebsiella pneumoniae isolates were identified by standard methods. Antibiotic susceptibility testing, screening for Extended-spectrum β lactamase (ESBL) production, Carbapenem resistance, carbapenemase production, and susceptibility to CAZ/AVI were done according to the CLSI guidelines. Results: Of the 255 neonates clinically suspected as neonatal sepsis, only 136 (53.3%) had positive culture results, out of the 136 culture-proven cases, 72 (52.9%) were positive for Klebsiella pneumoniae, of them ESBL producers were 92% (n=66) and CRKP was 32% of isolates (n=23). All of the CRKP were Carbapenamase producers (39% serine-type and 61% MBL type). Serine Carbapenamase and MBL producers showed high resistance against CAZ/AVI with a percentage of 77.8% and 100% respectively. Conclusion: The prevalence of CRKP is alarming in our NICU especially in the presence of neonatal risk factors like; neutropenia, central line fixation, and premature rupture of membranes. CAZ/AVI is an unsuitable option for the treatment of this type of resistant bacteria because of its high resistance.
- 20 May 2021
- Published by Egyptian Knowledge Bank in Microbes and Infectious Diseases
Open AccessCeftazidime/ Avibactam Efficiency tested In Vitro against Carbapenem-resistant Klebsiella pneumoniae isolated from Neonates with Sepsis
Background: Carbapenem-resistant Klebsiella pneumoniae (CRKP) emergence and dissemination, is an important healthcare concern due to its limited therapeutic options. Ceftazidime/avibactam (CAZ/AVI) is a recently approved antibiotic combination that may be effective in treating these resistant infections. The current study aimed to determine the prevalence of CRKP among clinical isolates from the neonatal intensive care unit (NICU) and to evaluate the in-vitro activity of CAZ/AVI against them. Methods: A total of 255 clinical samples were collected from neonates with suspected sepsis. All Klebsiella pneumoniae isolates were identified by standard methods. Antibiotic susceptibility testing, screening for Extended-spectrum β lactamase (ESBL) production, Carbapenem resistance, carbapenemase production, and susceptibility to CAZ/AVI were done according to the CLSI guidelines. Results: Of the 255 neonates clinically suspected as neonatal sepsis, only 136 (53.3%) had positive culture results, out of the 136 culture-proven cases, 72 (52.9%) were positive for Klebsiella pneumoniae, of them ESBL producers were 92% (n=66) and CRKP was 32% of isolates (n=23). All of the CRKP were Carbapenamase producers (39% serine-type and 61% MBL type). Serine Carbapenamase and MBL producers showed high resistance against CAZ/AVI with a percentage of 77.8% and 100% respectively. Conclusion: The prevalence of CRKP is alarming in our NICU especially in the presence of neonatal risk factors like; neutropenia, central line fixation, and premature rupture of membranes. CAZ/AVI is an unsuitable option for the treatment of this type of resistant bacteria because of its high resistance.